heartdiseasefacts.com
[ad_1]
At the 73rd Annual Scientific Sessions of the American College of Cardiology held in early April 2024, Gangaveli investigated heart failure hospitalization (HFH) rates in patients with preserved ejection fraction (HFpEF) and in diabetic patients on semaglutide. Their research was published. Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1RA) developed by Novo Nordisk, Ozempic for type 2 diabetes (T2D), Wegovy for obesity, and Rybelsus for T2D. (oral dosage form).
Highly effective clinical data in weight loss have led to significant uptake of this drug by patients and physicians, making it the leading GLP-1RA in the T2D and obesity markets. Semaglutide has been shown to reduce symptoms and increase weight loss in patients with HFpEF. A study by Gangavelli et al. investigated the effects of semaglutide on HFH and the need for outpatient intravenous (IV) diuresis in patients with HFpEF.
1.74 times lower incidence of HFH in semaglutide recipients
This retrospective cohort study included patients with HFpEF and diabetes mellitus (DM) who were seen from 2020 to 2022 and then followed until December 31, 2022. 3,434 patients were seen. The 268 semaglutide users were matched with non-users aged 62 to 16 years, 69% female, 94% black, and had a body mass index. [BMI] 39 plus or minus 12.
During a mean follow-up period of 26 months, the incidence of HFH was 1.74 times higher (95% confidence interval) [CI] 1.05-3.1) lower in semaglutide recipients compared to non-recipients (54.75 vs. 95.77 per 1000 patient-years, p=0.022). In the diuretic clinic, IV diuresis rates were 2.28 times (95% CI 2.04 to 2.55) lower in patients receiving semaglutide compared with those not receiving semaglutide (568.4 vs. 1298.5 per 1000 patient-years, p=<0.001). All-cause hospitalization rates for semaglutide users were similar to those for non-users (rate ratio = 0.94; 95% CI 0.77-1.14)
Reduced need for outpatient IV diuresis
Patients with HFpEF and DM (particularly T2D) prescribed semaglutide had lower rates of HFH and less need for outpatient IV diuresis. A growing body of strong clinical data demonstrating the role of semaglutide in the treatment of T2D, obesity, HF, and chronic kidney disease suggests that semaglutide is likely to become an important treatment in the increasing prevalence of metabolic syndrome. I am. Global Data predicts that semaglutide will continue to be the market-leading GLP-1RA, based on increasing use of semaglutide in type 2 diabetes and obesity, and data supporting its use in the treatment of heart failure, with market sales of semaglutide in particular expected to increase significantly is predicted to increase. The end of the 2020s.
Access the most comprehensive company profiles on the market with GlobalData. Save research time. Increase competitiveness.
Company Profile – Free Sample
You will receive a download email shortly
We are confident in the unique quality of our company profile. However, we want you to make the decision that is most beneficial for your business, so we are offering free samples that you can download by submitting the form below.
by global data
[ad_2]
Source link
